MODULATION SAPP, SAAP ALPHA AND BDNF LEVELS IN INDIVIDUALS DIAGNOSED WITH FXS AND ASD

摘要

A method of treating and monitoring patient diagnosed with Autistic Spectrum disorder or Fragile X syndrome comprising measuring plasma biomarker levels of BDNF, sAPP, and sAPP alpha and adjusting the amount of a therapeutic compound according to the plasma levels of BDNF, sAPP and sAPPs. In one embodiment, the therapeutic compound is acamprosate.

主权项

1. A method of treating a patient, comprising the steps of:
contacting a first sample of plasma from a patient diagnosed with ASD or FXS with a first reagent that selectively binds to BDNF, a second reagent that selectively binds to sAPP, and a reagent that binds to sAPPα, determining the levels of BDNF, sAPP, and sAPPα in the sample of plasma; administering at least one compound to the patient; binding a second sample of plasma from the patient with the first reagent that selectively binds to BDNF, the second reagent that selectively binds to sAPP, and the reagent that binds to sAPPα; determining if there is a change in the levels of BDNF, sAPP, and sAPPα in the patient's plasma; and adjusting the amount of the compound administered to the patient in response to the change in BDNF, sAPP, and sAPPα levels determined in the patient's plasma samples.